Comparative ASCL1 Interactome Analysis Reveals CDK2–Cyclin A2 as Suppressors of Differentiation in MYCN -Amplified Neuroblastoma

Read full text
Authors: Lidiya Mykhaylechko, Roshna L. Gomez, Laura M. Woods, Evangelia K. Papachristou, Revathy Ramachandran, Jethro Lundie-Brown, Rosalind Drummond, Daniel Marcos, Fiona M.Y. Abou Grealy, Shakhzada Ibragimova, Fahad R. Ali, Jason S. Carroll
+1 more Anna Philpott
Cited by: 0
References: 87

Abstract

Neuroblastoma is a heterogeneous pediatric cancer arising from developmentally arrested neuronal precursors, in which restoring differentiation offers therapeutic promise. Achaete-scute homolog 1 (ASCL1), a proneural transcription factor, is widely expressed in neuroblastoma and can drive either proliferation or differentiation depending on the cellular context. In this study, we show that distinct MYCN-amplified neuroblastoma cell lines exhibit differing differentiation responses to ASCL1 overexpression. By comparing genome-wide ASCL1 chromatin binding, transcriptional changes, and protein-protein interactions, we found that ASCL1 binds more extensively to neuronal proteins in a cell line that is more susceptible to ASCL1-driven differentiation but associates with cell-cycle regulators in less responsive cells. We show that cyclin-dependent kinase 2 (CDK2)-cyclin A2 bind ASCL1 in less responsive cells, with CDK-mediated phosphorylation of ASCL1 limiting the ability of ASCL1 to drive differentiation. IMPLICATIONS: Our study reveals that context-dependent interactions of ASCL1 with protein partners on the chromatin control its ability to reengage a differentiation program in neuroblastoma.

Fields of Study & Subjects

Neuroblastoma Research and Treatments Cancer-related Molecular Pathways Microtubule and mitosis dynamics

Publication details

Journal / source
Molecular Cancer Research
Publisher
American Association for Cancer Research (AACR)
Volume
24
Issue
8
Pages
675–693
Publication date
14 April 2026
Language
EN